Gravity Analytica

GE HealthCare Receives FDA Clearance for Head-Only SIGNA MAGNUS 3.0T MRI System

GEHCV 11.13.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-12-01

Name of Upcoming Event:Radiological Society of North America (RSNA) Annual Meeting

Full Press Release SEC Filings Our GEHCV Tweets

About Gravity Analytica

Recent Filings

12.12.2024 - 8-K Current report

New MRI technology aims to advance neuroimaging and biomarker research

CHICAGO--(BUSINESS WIRE)--Nov. 13, 2024--GE HealthCare(Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNATM MAGNUS,ⁱa 3.0T high-performance, head-only magnetic resonance imaging (MRI) scanner. This system offers new capabilities for both clinical imaging and neuroscience with the potential to aid in the detection of neurological, oncological, and psychiatric conditions.

The FDA clearance ofSIGNA MAGNUSunderscores the advances made byGE HealthCarein neuroimaging. It features an innovative asymmetrical, high-efficiency, head-only gradient coil design, which achieves higher gradient performance due to its reduced inner diameter, specifically tailored for neuroimaging. The asymmetrical design shifts the gradient isocenter to the patient edge of the coil rather than its geometric center, enabling patient head access and avoiding shoulder width constraints. This head-only design allows MAGNUS to deliver a gradient amplitude and slew rate far surpassing those of conventional 60cm or 70cm bore whole-body MRI systems, marking a significant advancement in MRI technology for neuroimaging applications.

"Obtaining FDA clearance further validates our commitment to not only innovating but also in delivering clinical technologies that have real-world impact," saidJason Polzin,GM, MR Applications Platform and Research Technologies,GE HealthCare. "WithSIGNA MAGNUS, we are providing neuroradiologists and neuroscience researchers a tool that supports advanced imaging and biomarker research and discovery previously impossible on conventional systems. It is our intent to makeSIGNA MAGNUSwidely available as a fully cleared commercial product."

A New Standard for Neuroimaging and Biomarker Discovery

SIGNA MAGNUSoffers exceptional precision, enabling high-resolution, high signal-to-noise ratio imaging, advanced diffusion techniques, and short scan times. To date, four investigational MAGNUS systems have been installed atWalter Reed National Military Medical Center,University of Iowa,University of Wisconsin– Madison and Brigham and Women’s Hospital.

Dr.Vince A. Magnotta, PhD, Director of the MR Research Facility and Professor of Radiology –Division of Neuroradiology,University of Iowa, praised the FDA clearance, stating, "FDA clearance is important because there’s a broad need for new biomarkers to study neurodegenerative disorders, and there’s an opportunity to better understand what’s happening in psychiatric disorders."

GE HealthCarehas demonstrated leadership in high-performance gradient technology with the introduction of HyperG gradients, one of the most efficient gradient coils on the marketⁱⁱ, in the SIGNA MAGNUS system. The innovative asymmetric head-only design of the HyperG gradient coil invokes significantly less Peripheral Nerve Stimulation (PNS) thus maximizing the actual use of the system’s gradient performance for both clinical and research scanning.

The HyperG gradient technology achieves remarkable performance levels of300 mT/m and 750 T/m/s, enabling faster image acquisition while using the same power requirement as the whole-body SIGNA Premier 3.0T system. Shorter scan times mean less time spent in the MRI machine, which is particularly beneficial for patients who may have difficulty remaining still or those with claustrophobia. Improved gradient strengths lead to enhanced spatial resolution and image clarity. This can result in accurate diagnoses, allowing healthcare providers to detect subtle abnormalities and provide better treatment options.

Clinical and Research Excellence

The enhanced capabilities of the SIGNA MAGNUS system provide ultra-high anatomical resolution with shorter scan times. Its ability to visualize brain function, microstructure, and micro-vasculature through innovations such as ODEN (Oscillating Gradient Diffusion Encoding) which uses oscillating gradients to provide cellularity contrast which can be important for neurological oncology. Our intention is to leverage the high-gradient performance ofSIGNA MAGNUScapabilities to allow for advanced research scanning such as high B-value diffusion imaging, fMRI for investigating the BOLD (Blood Oxygen Level Dependent) response and measurement of slow CSF (Cerebral Spinal Fluid) flow. This marks a transformative step forward in advancing neuroscience research.

“We're very excited about the capabilitiesSIGNA MAGNUSprovides,” said Kawin Setsompop, PhD, Associate Professor of Radiology and by courtesy Electrical Engineering, Associate Chair of Research Strategic Development,Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.”

SIGNA MAGNUSwill be available for both forward production and upgrades from compatible SIGNA Premier systems. This means that existing facilities can upgrade to this advanced technology, expanding access to high-performance imaging without the need for entirely new systems, additional power or cooling. This FDA clearance empowers the clinical community to adoptSIGNA MAGNUSinto routine practice and further advances research in critical areas such as neurodegenerative, neuro-oncology and psychiatric disorders.

Learn more aboutSIGNA MAGNUSat theRadiological Society of North America(RSNA) Annual Meeting, December 1–4, 2024, inChicago, or online atgehealthcare.com.

AboutGE HealthCare Technologies Inc.GE HealthCareis a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years,GE HealthCareis advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, andPharmaceutical Diagnosticsbusinesses help improve patient care from diagnosis, to therapy, to monitoring. We are a$19.6 billionbusiness with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us onLinkedIn,X,Facebook,Instagram, andInsightsfor the latest news, or visit our websitehttps://www.gehealthcare.comfor more information.

ⁱSIGNATM MAGNUS is 510(k) cleared with the FDA. Not yet CE Marked. Not available for sale in all regions.ⁱⁱGE HealthCaredata on file

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241113845220/en/

GE HealthCare Media Contact:Kimberly SchmohlM +1 929 289 1937kimberly.schmohl@gehealthcare.com

Source:GE HealthCare

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com